This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2010 Jan 7;362(1):88-9.

doi: 10.1056/NEJMc0910893. Epub 2009 Dec 23.

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza

Aditya H Gaur, Bindiya Bagga, Subrata Barman, Randall Hayden, Aubrey Lamptey, James M Hoffman, Deepa Bhojwani, Patricia M Flynn, Elaine Tuomanen, Richard Webby

PMID: 20032317
DOI: 10.1056/NEJMc0910893

Case Reports

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza

Aditya H Gaur et al. N Engl J Med. 2010.

. 2010 Jan 7;362(1):88-9.

doi: 10.1056/NEJMc0910893. Epub 2009 Dec 23.

Authors

Aditya H Gaur, Bindiya Bagga, Subrata Barman, Randall Hayden, Aubrey Lamptey, James M Hoffman, Deepa Bhojwani, Patricia M Flynn, Elaine Tuomanen, Richard Webby

PMID: 20032317
DOI: 10.1056/NEJMc0910893

No abstract available

PubMed Disclaimer

Similar articles

Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus.
Wijaya L, Chua YY, Cui L, Chan K, Tan BH. Wijaya L, et al. Singapore Med J. 2011 Jul;52(7):481-5. Singapore Med J. 2011. PMID: 21808957
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
van der Vries E, Stelma FF, Boucher CA. van der Vries E, et al. N Engl J Med. 2010 Sep 30;363(14):1381-2. doi: 10.1056/NEJMc1003749. N Engl J Med. 2010. PMID: 20879894 No abstract available.
The use of antiviral agents for the management of severe influenza.
Smith JR, Ariano RE, Toovey S. Smith JR, et al. Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Crit Care Med. 2010. PMID: 19935416 Review.
Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Kawai N, Ikematsu H, Hirotsu N, Maeda T, Kawashima T, Tanaka O, Yamauchi S, Kawamura K, Matsuura S, Nishimura M, Iwaki N, Kashiwagi S. Kawai N, et al. Clin Infect Dis. 2009 Dec 15;49(12):1828-35. doi: 10.1086/648424. Clin Infect Dis. 2009. PMID: 19911968
Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).
Chan-Tack KM, Kim C, Moruf A, Birnkrant DB. Chan-Tack KM, et al. Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb 10. Antivir Ther. 2015. PMID: 25667992 Review.

See all similar articles

Cited by

A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP. Tarbet EB, et al. J Antimicrob Chemother. 2014 Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28. J Antimicrob Chemother. 2014. PMID: 24777908 Free PMC article.
Pandemic (H1N1) 2009 infection in patients with hematologic malignancy.
Liu C, Schwartz BS, Vallabhaneni S, Nixon M, Chin-Hong PV, Miller SA, Chiu C, Damon L, Drew WL. Liu C, et al. Emerg Infect Dis. 2010 Dec;16(12):1910-7. doi: 10.3201/eid1612.100772. Emerg Infect Dis. 2010. PMID: 21122221 Free PMC article.
Residue-based design of small molecule inhibitor for H1N1, H5N1 and H7N1 mutants.
Tou WI, Chang KL, Chang TT, Lee CC, Chen CY. Tou WI, et al. J Mol Model. 2016 Jan;22(1):4. doi: 10.1007/s00894-015-2875-y. Epub 2015 Dec 8. J Mol Model. 2016. PMID: 26645808
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Widmer N, et al. Clin Pharmacokinet. 2010 Nov;49(11):741-65. doi: 10.2165/11534730-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20923248 Review.
I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.
LeGoff J, Rousset D, Abou-Jaoudé G, Scemla A, Ribaud P, Mercier-Delarue S, Caro V, Enouf V, Simon F, Molina JM, van der Werf S. LeGoff J, et al. PLoS One. 2012;7(8):e37095. doi: 10.1371/journal.pone.0037095. Epub 2012 Aug 24. PLoS One. 2012. PMID: 22936969 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information